PetVivo to Exhibit Spryng with OsteoCushion™ Technology at the Veterinary Meeting and Expo Conference in Orlando, Florida on January 25-29, 2025
PetVivo Holdings (OTCQB: PETV) announced its participation in the Veterinary Meeting & Expo Conference from January 25-29, 2025, in Orlando, Florida. The company will showcase its flagship product, Spryng with OsteoCushion Technology, at booth #1825.
Spryng is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles. The product works by adsorbing onto animals' joint synovial lining and integrating with subsynovial tissue, helping restore proper joint mechanics. It's designed to manage noninfectious joint pain, including joint instability, degenerative joint disease, and osteoarthritis.
VMX, the largest veterinary conference in the United States, will provide PetVivo an opportunity to demonstrate Spryng's benefits to leading veterinarian surgeons and showcase its effectiveness in treating horses and companion animals across the U.S.
PetVivo Holdings (OTCQB: PETV) ha annunciato la sua partecipazione alla Veterinary Meeting & Expo Conference che si svolgerà dal 25 al 29 gennaio 2025 a Orlando, Florida. L'azienda presenterà il suo prodotto di punta, Spryng con tecnologia OsteoCushion, allo stand #1825.
Spryng è un dispositivo medico veterinario iniettabile intra-articolare composto da microparticelle di matrice extracellulare sterilizzata. Il prodotto agisce assorbendosi sul rivestimento sinoviale delle articolazioni degli animali e integrandosi con il tessuto sottosinoviale, aiutando a ripristinare una corretta meccanica articolare. È progettato per gestire il dolore articolare non infettivo, inclusi l'instabilità articolare, le malattie articolari degenerative e l'osteoartrosi.
VMX, la più grande conferenza veterinaria negli Stati Uniti, offrirà a PetVivo l'opportunità di dimostrare i benefici di Spryng ai chirurghi veterinari di punta e mostrare la sua efficacia nel trattamento di cavalli e animali da compagnia negli Stati Uniti.
PetVivo Holdings (OTCQB: PETV) anunció su participación en la Veterinary Meeting & Expo Conference que se llevará a cabo del 25 al 29 de enero de 2025 en Orlando, Florida. La compañía presentará su producto insignia, Spryng con tecnología OsteoCushion, en el stand #1825.
Spryng es un dispositivo médico veterinario inyectable intraarticular compuesto por micropartículas de matriz extracelular esterilizada. El producto actúa adsorbiéndose en el revestimiento sinovial de las articulaciones de los animales e integrándose con el tejido subsinovial, ayudando a restaurar la mecánica adecuada de las articulaciones. Está diseñado para tratar el dolor articular no infeccioso, incluyendo inestabilidad articular, enfermedades articulares degenerativas y osteoartritis.
VMX, la conferencia veterinaria más grande de los Estados Unidos, le brindará a PetVivo la oportunidad de demostrar los beneficios de Spryng a destacados cirujanos veterinarios y mostrar su efectividad en el tratamiento de caballos y animales de compañía en todo el país.
PetVivo Holdings (OTCQB: PETV)는 2025년 1월 25일부터 29일까지 플로리다주 올랜도에서 열리는 Veterinary Meeting & Expo Conference에 참여한다고 발표했습니다. 이 회사는 부스 #1825에서 주력 제품인 OsteoCushion 기술이 적용된 Spryng을 선보일 예정입니다.
Spryng은 멸균된 세포외 기질 미세입자로 구성된 관절 내 주사 가능한 수의학 의료 기기입니다. 이 제품은 동물의 관절 활막에 흡착되고 피하 활막 조직과 통합되어 올바른 관절 역학을 복원하는 데 도움을 줍니다. 비감염성 관절 통증, 관절 불안정성, 퇴행성 관절 질환 및 골관절염을 관리하도록 설계되었습니다.
VMX는 미국에서 가장 큰 수의학 컨퍼런스이며, PetVivo가 Spryng의 이점을 저명한 수의외과 의사들에게 시연하고 미국 전역의 말과 반려동물 치료에 있어 그 효과를 보여줄 수 있는 기회를 제공합니다.
PetVivo Holdings (OTCQB: PETV) a annoncé sa participation à la Veterinary Meeting & Expo Conference qui se déroulera du 25 au 29 janvier 2025 à Orlando, en Floride. L'entreprise présentera son produit phare, Spryng avec technologie OsteoCushion, au stand #1825.
Spryng est un dispositif médical vétérinaire injectable intra-articulaire composé de microparticules de matrice extracellulaire stérilisées. Le produit agit en s'adsorbant sur la membrane synoviale des articulations des animaux et en s'intégrant dans le tissu subsynovial, aidant à restaurer la mécanique articulaire appropriée. Il est conçu pour gérer la douleur articulaire non infectieuse, y compris l'instabilité articulaire, les maladies articulaires dégénératives et l'arthrose.
La VMX, la plus grande conférence vétérinaire des États-Unis, offrira à PetVivo l'opportunité de démontrer les avantages de Spryng à des chirurgiens vétérinaires de premier plan et de mettre en avant son efficacité dans le traitement des chevaux et des animaux de compagnie à travers les États-Unis.
PetVivo Holdings (OTCQB: PETV) gab die Teilnahme an der Veterinary Meeting & Expo Conference bekannt, die vom 25. bis 29. Januar 2025 in Orlando, Florida, stattfindet. Das Unternehmen wird sein Flaggschiffprodukt, Spryng mit OsteoCushion-Technologie, am Stand #1825 präsentieren.
Spryng ist ein intra-artikuläres injizierbares veterinärmedizinisches Gerät, das aus sterilisierten, extrazellulären Matrixmikropartikeln besteht. Das Produkt wirkt, indem es auf die synoviale Auskleidung der Gelenke von Tieren adsorbiert und mit dem subsynovialen Gewebe integriert, um die richtige Gelenkmechanik wiederherzustellen. Es ist darauf ausgelegt, nicht-infektiöse Gelenkschmerzen zu behandeln, einschließlich Gelenkinstabilität, degenerativer Gelenkerkrankungen und Arthrose.
Die VMX, die größte veterinärmedizinische Konferenz in den Vereinigten Staaten, wird PetVivo die Möglichkeit bieten, die Vorteile von Spryng führenden veterinärmedizinischen Chirurgen zu demonstrieren und seine Wirksamkeit bei der Behandlung von Pferden und Haustieren in den USA zu präsentieren.
- Product has demonstrated beneficial results in treating horses and companion animals across the U.S.
- Company gains exposure at the largest veterinary conference in the United States
- None.
MINNEAPOLIS, MN, Jan. 14, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading provider of medical devices and biomedical therapeutics for equines and companion animals today announced it will be exhibiting at the Veterinary Meeting & Expo Conference to held from January 25th to January 29th, 2025, at the Orange County Convention Center, Exhibit Halls B, C and D, in Orlando, Florida.
PetVivo will exhibit its lead product, Spryng ™ with OsteoCushion™ Technology. Spryng is an intra-articular injectable veterinary medical device composed of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
VMX is the largest veterinary conference in the United States and plays host to many of the top industry professionals.
“We are incredibly excited to participate in this year’s VMX Conference. The VMX provides us an excellent opportunity to demonstrate to leading veterinarian surgeons our innovative medical device for the management of osteoarthritis, Spryng with OsteoCushion Technology,” said PetVivo CEO, John Lai. “We welcome the opportunity to support VMX and participate in this conference to explain the advantages of Spryng including the beneficial results we have witnessed when administered to horses and companion animals throughout the U.S.”
Visitors to the VMX Conference can see the Spryng exhibit at booth #1825 on January 26, 2025, 9:00 a.m. to 6:30 p.m., as well as on January 27, 2025, 9:00 a.m. to 5:30 p.m., January 28, 2025, 9:00 a.m. to 5:30 p.m. and January 29, 2025, 9:00 a.m. to 2:00 p.m.
For more information about Spryng, please contact info1@petvivo.com or visit petvivo.com and sprynghealth.com.
About PetVivo Holdings
PetVivo Holdings, Inc. (OTCQB: PETV, PETVW) is a biomedical device company focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The company is pursuing a strategy of developing and commercializing human therapies for the treatment of companion animals in capital and time efficient ways. A key component of this strategy is an accelerated timeline to revenues for veterinary medical devices that can enter the market much earlier than more stringently regulated human pharmaceuticals and biologics.
PetVivo has developed a robust pipeline of products for the medical treatment of animals and people, with a portfolio of 21 patents that protect the company's biomaterials, products, production processes and methods of use. The company’s commercially launched flagship product, Spryng™ with OsteoCushion™ Technology, is a veterinarian-administered, intra-articular injectable designed for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses.
For more information about PetVivo and its revolutionary Spryng with OsteoCushion Technology, email info1@petvivo.com or visit petvivo.com or sprynghealth.com.
Disclosure Information
PetVivo uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the company’s Investor Relations website, in addition to following the company’s press releases, SEC filings, public conference calls, presentations and webcasts.
Forward-Looking commercial Statements
The foregoing information regarding PetVivo Holdings, Inc. (the “Company”) may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2024 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216
FAQ
What is PetVivo's Spryng with OsteoCushion Technology (PETV) and how does it work?
When and where will PetVivo (PETV) exhibit at the VMX Conference 2025?
What conditions does PetVivo's Spryng (PETV) treat in animals?
What are the exhibition hours for PetVivo (PETV) at the 2025 VMX Conference?
